Navigation Links
CV Therapeutics' Anti-Ischemic Agent Ranexa(R) Significantly Reduces HbA1c and Other Markers of Diabetes in MERLIN TIMI-36
Date:11/6/2007

ardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases.

CV Therapeutics' approved product, Ranexa(R) (ranolazine extended-release tablets), is indicated for the treatment of chronic angina in patients who have not achieved an adequate response with other antianginal drugs, and should be used in combination with amlodipine, beta-blockers or nitrates.

CV Therapeutics also has other clinical and preclinical drug development candidates and programs, including regadenoson, which is being developed for potential use as a pharmacologic stress agent in myocardial perfusion imaging studies, and CVT-6883, which is being developed as a potential treatment for cardiopulmonary diseases. Regadenoson and CVT-6883 have not been determined by any regulatory authorities to be safe or effective in humans for any use.

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including operating losses and fluctuations in operating results; capital requirements; regulatory review and approval of our products; special protocol assessment agreement; the conduct and timing of clinical trials; commercialization of products; market acceptance of products; product labeling; concentrated customer base; reliance on strategic partnerships and collaborations; uncertainties in drug development; uncertainties regarding intellectual property; and other risks detailed from time to time in CV Therapeutics' SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2007. CV Therapeutics disclaims any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE CV Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)...  Dr. Stephen Loyd , a recovering substance ... National Recovery Month, stars in a new television ad ... advocates were also joined by a Los ... her fiancée because of a preventable error in surgery ... of crack cocaine abuse. Proposition 46 would identify doctors ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire-iReach/ -- ChemImage ... paper discussing improvements in the development of ... for both normal and diseased tissue that ... simplifies surgical procedures, lowers surgical costs and ... procedures. The clinical and ...
(Date:9/17/2014)... Calif. , Sept. 17, 2014 ... Prostate Vanguard, an awareness campaign to educate men about ... needle biopsies of the prostate. Annually, a million ... gland through the rectum. Multi-parametric MRI (MP-MRI) of the ... prostate cancer (CSPC). Men need to be fully ...
Breaking Medicine Technology:Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 2Doctor Recovering From 100-Pill-A-Day Addiction Stars In New Ad Supporting Prop 46; Appears At White House for National Recovery Month, Says Consumer Watchdog Campaign 3Patient Outcomes Improve When Molecular Chemical Imaging Technology Is Used to Aid Robotic Surgical Procedures, According to New White Paper 2Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3
... 2 MedAvante, Inc., the leader in centralized evaluation of central nervous ... Service for trials assessing Alzheimer,s Disease. Its CQC Services are already in use ... in the United States , Europe , Asia , ... , , ...
... HARBIN, China , June 2 /PRNewswire-Asia-FirstCall/ ... a,developer, manufacturer and distributor of botanical products,bio-pharmaceuticals and traditional Chinese ... a conference call at 9:00 a.m. Eastern Time ... for the second quarter of its,fiscal year 2010, ended ...
Cached Medicine Technology:MedAvante Launches Service to Boost Reliability of Assessments to Reduce Risk of Failed Alzheimer's Disease Trials 2MedAvante Launches Service to Boost Reliability of Assessments to Reduce Risk of Failed Alzheimer's Disease Trials 3Renhuang Schedules Conference Call to Discuss FY 2010 Second Quarter Results 2Renhuang Schedules Conference Call to Discuss FY 2010 Second Quarter Results 3
(Date:9/17/2014)... 17, 2014 Boston Children’s Museum ... a monthly concert series, introducing young Museum visitors ... Top, America’s premier national platform celebrating the stories, ... of the young musicians featured will also be ... Children’s Museum is fortunate to partner with the ...
(Date:9/17/2014)... 2014 StartX , a nonprofit ... raising rounds of funding at its Summer Demo Day ... and media, was the first such gathering held at ... the university. The presentations were delivered on an expansive ... Labs, a 2,000 square foot life science facility that ...
(Date:9/17/2014)... The in vitro diagnostics (IVD) marketplace is a ... molecular diagnostics for conditions such as infectious diseases, sexually-transmitted ... market value is projected to be worth around USD ... drivers of the market’s growth include the shift to ... the explosion for raid and minimally-invasive diagnostic tools; demand ...
(Date:9/17/2014)... News) -- Managing diabetes, quitting smoking, controlling high blood ... the risk for dementia -- even late in life, ... Report 2014, commissioned by Alzheimer,s Disease International, revealed that ... percent. The study noted that obesity and an inactive ... as high blood pressure. The researchers suggested ...
(Date:9/17/2014)... be able to reduce the need for invasive biopsies ... disease lupus. , In a new study, researchers developed ... nephritis kidney inflammation to interstitial fibrosis, scarring ... kidney biopsy is the only existing way to reach ... , The model could also be used to monitor ...
Breaking Medicine News(10 mins):Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 2Health News:World In Vitro Diagnostics Market Analysed by VPG in In-demand Research Report Available at MarketPublishers.com 3Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 2Health News:Healthy Lifestyle Changes Linked to Reduced Risk for Dementia 3Health News:Math model designed to replace invasive kidney biopsy for lupus patients 2
... fiscal 2008 net sales of $20.4 million versus $24.1 ... million in the same quarter ... with initial shipments expected during the second half ... Natural,Alternatives International, Inc. ("NAI") (Nasdaq: NAII ), a leading,formulator, ...
... NEWPORT BEACH, Calif., Feb. 7 Nationwide,Health Properties, Inc. ... will,release its fourth quarter earnings on Monday, February 25, ... Stock Exchange. The Company will host a,conference call on ... a.m. Eastern time) in order to present the Company,s ...
... research showed it greatly boosted pregnancy chances , , THURSDAY, ... fertilization can increase their chances of becoming pregnant by ... a preliminary study suggests. , , About 10 percent ... many opt for in vitro fertilization, in which a ...
... European Hematology Association (EHA) and the American Society ... and Serena Kimi Perna, MD, as the recipients ... which was established to help strengthen ties between ... International Fellowship Award provides hematologists in training or ...
... Memory Pharmaceuticals,Corp. (Nasdaq: MEMY ) today ... President & Chief Executive Officer. In support of ... MPM,Capital, Great Point Partners, Oxford Biosciences and Venrock, ... who has served as the,Company,s President & Chief ...
... Perot Systems Continues Its Thought Leadership Series with a ... Between Dr. Kevin Fickenscher and Dr. Suzanne Delbanco, ... continue to be a major concern for leaders in ... the World, Dr.,Kevin Fickenscher, Chief Medical Officer & Executive ...
Cached Medicine News:Health News:Natural Alternatives International, Inc. Announces Second Quarter Results 2Health News:Natural Alternatives International, Inc. Announces Second Quarter Results 3Health News:Natural Alternatives International, Inc. Announces Second Quarter Results 4Health News:Natural Alternatives International, Inc. Announces Second Quarter Results 5Health News:NHP Announces Fourth Quarter Earnings Release Date and Conference Call/Webcast 2Health News:NHP Announces Fourth Quarter Earnings Release Date and Conference Call/Webcast 3Health News:Acupuncture May Aid In Vitro Fertilization 2Health News:Acupuncture May Aid In Vitro Fertilization 3Health News:Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer 2Health News:Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer 3Health News:Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer 4Health News:Healthcare Tech and the World: Podcast Examines The Challenges & Opportunities for Change in the Healthcare Industry 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: